T. Rowe Price Associates’s Fate Therapeutics FATE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$53K Buy
46,855
+8,806
+23% +$9.96K ﹤0.01% 2997
2025
Q1
$31K Hold
38,049
﹤0.01% 2977
2024
Q4
$63K Sell
38,049
-27,170
-42% -$45K ﹤0.01% 2895
2024
Q3
$229K Hold
65,219
﹤0.01% 2600
2024
Q2
$214K Sell
65,219
-209,070
-76% -$686K ﹤0.01% 2568
2024
Q1
$2.01M Buy
274,289
+219,932
+405% +$1.61M ﹤0.01% 1558
2023
Q4
$204K Sell
54,357
-923,505
-94% -$3.47M ﹤0.01% 2534
2023
Q3
$2.07M Buy
977,862
+15,704
+2% +$33.3K ﹤0.01% 1443
2023
Q2
$4.58M Sell
962,158
-537,874
-36% -$2.56M ﹤0.01% 1209
2023
Q1
$8.55M Sell
1,500,032
-1,159,026
-44% -$6.61M ﹤0.01% 1088
2022
Q4
$26.8M Sell
2,659,058
-482,595
-15% -$4.87M ﹤0.01% 838
2022
Q3
$70.4M Sell
3,141,653
-1,841,850
-37% -$41.3M 0.01% 561
2022
Q2
$123M Buy
4,983,503
+72,136
+1% +$1.79M 0.02% 602
2022
Q1
$190M Buy
4,911,367
+977,429
+25% +$37.9M 0.02% 540
2021
Q4
$230M Sell
3,933,938
-22,557
-0.6% -$1.32M 0.02% 524
2021
Q3
$235M Buy
3,956,495
+846,663
+27% +$50.2M 0.02% 492
2021
Q2
$270M Sell
3,109,832
-39,274
-1% -$3.41M 0.03% 476
2021
Q1
$260M Sell
3,149,106
-361,864
-10% -$29.8M 0.03% 481
2020
Q4
$319M Buy
3,510,970
+1,173,625
+50% +$107M 0.03% 409
2020
Q3
$93.4M Buy
2,337,345
+1,075,400
+85% +$43M 0.01% 675
2020
Q2
$43.3M Buy
1,261,945
+382,982
+44% +$13.1M 0.01% 895
2020
Q1
$19.5M Sell
878,963
-103,618
-11% -$2.3M ﹤0.01% 1082
2019
Q4
$19.2M Sell
982,581
-206,681
-17% -$4.04M ﹤0.01% 1195
2019
Q3
$18.5M Buy
1,189,262
+1,423
+0.1% +$22.1K ﹤0.01% 1174
2019
Q2
$24.1M Sell
1,187,839
-60,943
-5% -$1.24M ﹤0.01% 1125
2019
Q1
$21.9M Buy
1,248,782
+332,158
+36% +$5.84M ﹤0.01% 1153
2018
Q4
$11.8M Buy
916,624
+103,429
+13% +$1.33M ﹤0.01% 1284
2018
Q3
$13.2M Buy
813,195
+24,099
+3% +$393K ﹤0.01% 1326
2018
Q2
$8.95M Sell
789,096
-173,677
-18% -$1.97M ﹤0.01% 1366
2018
Q1
$9.4M Buy
962,773
+437,166
+83% +$4.27M ﹤0.01% 1342
2017
Q4
$3.21M Buy
+525,607
New +$3.21M ﹤0.01% 1470